Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report

被引：0
|
作者：
Tang, Q. [1 ]
Xu, S. [1 ]
机构：
[1] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
KANK1-ALK; Alectinib; lung adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.02-01
引用
收藏
页码：S673 / S674
页数：2
相关论文
共 50 条
  • [1] Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report
    Tang, Quanying
    Li, Tong
    Ren, Fan
    Li, Xuanguang
    Cao, WeiBo
    Yu, Haochuan
    Mao, Fuling
    Cao, Cancan
    Zu, Lingling
    Xu, Song
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (02):
  • [2] Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
    Gu, Xiaodong
    Wang, Wenxian
    Wu, Wei
    Zhang, Yiping
    Shao, Lan
    Santarpia, Mariacarmela
    Christopoulos, Petros
    Myall, Nathaniel J.
    Shi, Zhiyong
    Lou, Guangyuan
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 902 - 909
  • [3] A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
    Xiang Tian
    Qiong Liao
    Qidong Yang
    Lin Chen
    Mingzhe Xiao
    Yuanjian Cheng
    [J]. Investigational New Drugs, 2022, 40 : 850 - 853
  • [4] A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
    Tian, Xiang
    Liao, Qiong
    Yang, Qidong
    Chen, Lin
    Xiao, Mingzhe
    Cheng, Yuanjian
    [J]. INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 850 - 853
  • [5] A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
    Deng, Ling
    Tian, Panwen
    Qiu, Zhixin
    Wang, Ke
    Li, Yalun
    [J]. OPEN LIFE SCIENCES, 2022, 17 (01): : 846 - 850
  • [6] Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report
    Cesaro, Cristiano
    Caterino, Umberto
    Perrotta, Fabio
    Masi, Umberto
    Cotroneo, Alessandra
    Cianci, Roberta
    Zamparelli, Enzo
    Cesaro, Flavio
    Amore, Dario
    Rocco, Danilo
    [J]. MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (03)
  • [7] High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
    Li, Yan
    Duan, Peng
    Guan, Yan
    Chen, Qing
    Grenda, Anna
    Christopoulos, Petros
    Denis, Marc G.
    Guo, Qisen
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (01) : 100 - 110
  • [8] A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma
    Liu, Zhenkun
    Wu, Qiang
    Li, Wen
    Li, Pengfei
    Huang, Lin
    Wang, Ting
    Zhou, Qinghua
    [J]. LUNG CANCER, 2023, 186
  • [9] Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report
    Lin, Jieheng
    Wang, Wenping
    Lin, Jietao
    Chen, Ruilian
    Cao, Yang
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (20) : 5326 - 5329
  • [10] Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib A case report
    Ning, Shangkun
    Shi, Congcong
    Zhang, Huifang
    Li, Jinpeng
    [J]. MEDICINE, 2021, 100 (51)
12345